Group 1 - The company reported a 21% growth in its U.S. segment for the most recent quarter, indicating strong performance [1] - The company announced the acquisition of the remaining portion of OneOncology, which it did not previously own, enhancing its market position [1] - The acquisition of both Retina Consultants of America and OneOncology is expected to strengthen the company's MSO strategy [2]